Literature DB >> 33622681

Comparison between 1973 and 2004/2016 WHO grading systems in patients with Ta urothelial carcinoma of urinary bladder.

Claudia Collà Ruvolo1,2, Christoph Würnschimmel3,4, Mike Wenzel3,5, Luigi Nocera3,6, Gianluigi Califano2, Zhe Tian3, Shahrokh F Shariat7,8,9,10,11,12, Fred Saad3, Felix K H Chun5, Alberto Briganti6, Paolo Verze13, Ciro Imbimbo2, Vincenzo Mirone2, Pierre I Karakiewicz3.   

Abstract

AIMS: To compare the 1973 WHO and the 2004/2016 WHO grading systems in patients with urothelial carcinoma of urinary bladder (UCUB), since no consensus has been made which classification should supersede the other and since both are recommended in clinical practice.
METHODS: Newly diagnosed patients with Ta UCUB treated with transurethral resection of bladder tumour were abstracted from the Surveillance, Epidemiology and End Results database (2010-2016). Kaplan-Meier plots and multivariable Cox regression models (CRMs) tested cancer-specific mortality (CSM), according to 1973 WHO (G1 vs G2 vs G3) and to 2004/2016 WHO (low-grade vs high-grade) grading systems.
RESULTS: Of 35 986 patients, according to 1973 WHO grading system, 8165 (22.7%) were G1, 17 136 (47.6%) were G2 and 10 685 (29.7%) were G3. According to 2004/2016 WHO grading system, 24 961 (69.4%) were low-grade versus 11 025 (30.6%) high-grade. In multivariable CRMs, G3 (HR: 2.05, p<0.001), relative to G1, and high-grade(HR: 2.13, p<0.001), relative to low-grade, predicted higher CSM. Conversely, G2 (p=0.8) was not an independent predictor. The multivariable models without consideration of either grading system were 74% accurate in predicting 5-year CSM. After addition of 1973 WHO or 2004/2016 WHO grade, the accuracy increased to 76% and 77%, respectively.
CONCLUSIONS: From a statistical standpoint, it appears that the 2004/2016 WHO grading system holds a small, although measurable advantage over the 1973 WHO grading system. Other considerations, such as intraobserver and interobserver variability may represent an additional matric to consider in deciding which grading system is better. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  urinary bladder; urologic diseases; urologic neoplasms

Mesh:

Year:  2021        PMID: 33622681     DOI: 10.1136/jclinpath-2021-207400

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  2 in total

1.  Biological distinction between grades 2 and 3 with respect to intravesical recurrence in T1 high-grade bladder tumors: a retrospective study.

Authors:  Akinaru Yamamoto; Atsunari Kawashima; Toshihiro Uemura; Gaku Yamamichi; Eisuke Tomiyama; Yoko Koh; Makoto Matsushita; Taigo Kato; Koji Hatano; Motohide Uemura; Norio Nonomura
Journal:  BMC Urol       Date:  2022-04-12       Impact factor: 2.264

2.  Comparison between 1973 and 2004/2016 World Health Organization grading in upper tract urothelial carcinoma treated with radical nephroureterectomy.

Authors:  Claudia Collà Ruvolo; Christoph Würnschimmel; Mike Wenzel; Luigi Nocera; Giuseppe Celentano; Francesco Mangiapia; Zhe Tian; Shahrokh F Shariat; Fred Saad; Felix H C Chun; Alberto Briganti; Nicola Longo; Vincenzo Mirone; Pierre I Karakiewicz
Journal:  Int J Clin Oncol       Date:  2021-06-06       Impact factor: 3.402

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.